Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.

Al Nawakil C; Park S; Chapuis N; Dreyfus F; Szwebel TA; Gibault L; Molina T; Hermine O; Bouscary D; Tamburini J

首页> 外文期刊>British Journal of Haematology >Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.

【24h】

Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.

机译：血小板生成素受体激动剂罗米洛司汀对自身免疫性血小板减少性紫癜的挽救疗法揭示了非霍奇金淋巴瘤。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Immune Thrombocytopenic Purpura (ITP) is an autoimmune disease that mainly results from a rapid splenic and hepatic clearance of autoantibody-loaded platelets from the circulation (Koehrer et al, 2010). Secondary causes of ITP must be excluded at diagnosis, including autoimmune conditions, chronic infection (e.g. Hepatitis C virus, human immunodeficiency virus) and lymphoproliferative disorders (LPD), particularly B-cell chronic lymphocytic leukaemia (B-CLL) (Cines et al, 2009). Treatment options for idiopathic ITP are. well defined, including steroids, intravenous immunoglobulins (IVIG) in acute ITP, and the anti-CD20 monoclonal antibody rituximab, splenectomy and immune suppressive drugs in chronic ITP (George, 2010).

机译：免疫性血小板减少性紫癜（ITP）是一种自身免疫性疾病，主要是由于循环中自身抗体加载的血小板从脾脏和肝脏的快速清除所致（Koehrer等，2010）。诊断时必须排除ITP的继发原因，包括自身免疫性疾病，慢性感染（例如丙型肝炎病毒，人类免疫缺陷病毒）和淋巴细胞增生性疾病（LPD），尤其是B细胞慢性淋巴细胞性白血病（B-CLL）（Cines等， 2009）。特发性ITP的治疗选择是。定义明确的药物，包括急性ITP中的类固醇，静脉免疫球蛋白（IVIG），以及慢性ITP中的抗CD20单克隆抗体利妥昔单抗，脾切除术和免疫抑制药物（George，2010）。

著录项

来源
《British Journal of Haematology》 |2012年第1期|共3页
作者
Al Nawakil C; Park S; Chapuis N; Dreyfus F; Szwebel TA; Gibault L; Molina T; Hermine O; Bouscary D; Tamburini J;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim. [J] . Al Nawakil C, Park S, Chapuis N, British Journal of Haematology . 2012,第1期

机译：血小板生成素受体激动剂罗米洛司汀对自身免疫性血小板减少性紫癜的挽救疗法揭示了非霍奇金淋巴瘤。
2. Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report [J] . Kouki Hoshino, Norifumi Harimoto, Ryo Muranushi, Surgical Case Reports . 2019,第1期

机译：血小板生成素受体激动剂成功切除特发性血小板减少性紫癜肝内胆管癌：一例
3. Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis [J] . Massaro Joyce Tumaini, Chen Yanhui, Ke Zhongling Platelets . 2019,第7期

机译：慢性免疫血小板减少紫癜儿童血小板生成素受体激动剂的疗效和安全性：Meta分析
4. Recomblnant Human Interferon a-2b Therapy, for Refractory Immyne Thrombocytopenic Purpura In Children [C] . M. Serban, V. Borla. C Petrescu, S. Arghirescu, Hemophilie-Symposion . 2004

机译：重组人类干扰素A-2B疗法，用于儿童难治性免疫血小板细胞脓性紫癜
5. Natural Toll-like receptor agonists in prophylactic vaccines for in situ vaccination lymphoma immunotherapy. [D] . Peng, Paul. 2016

机译：预防性疫苗中的天然Toll样受体激动剂，用于原位接种淋巴瘤免疫治疗。
6. Balancing Therapy with Thrombopoietin Receptor Agonists and Splenectomy in Refractory Immune Thrombocytopenic Purpura: A Case of Postsplenectomy Thrombocytosis Requiring Plateletpheresis [O] . Jacquelyn Zimmerman, Kelly J. Norsworthy, Robert Brodsky 2016

机译：血小板生成素受体激动剂和脾切除术在难治性免疫性血小板减少性紫癜中的平衡治疗：脾切除术后血小板增多症需要血小板减少的病例
7. Salvage therapy of Autoimmune Thrombocytopenic Purpura revealing non-Hodgkin Lymphoma by the thrombopoietin receptor agonist romiplostim [O] . Chadi Al-Nawakil, Sophie Park, Nicolas Chapuis, 2011

机译：自身免疫性血小板细胞催化剂的抢救治疗血管生成素受体激动剂romiplosim的非霍奇金淋巴瘤

Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.

摘要

著录项

相似文献

相关主题

期刊订阅